Clinical Trial on a Novel Blood Pumping System in 4008A Hemodialysis Machine

D.med Consulting GmbH1 site in 1 country8 target enrollmentJanuary 19, 2022

ConditionsRenal Dialysis

Overview

Phase: N/A
Intervention: Not specified
Conditions: Renal Dialysis
Sponsor: D.med Consulting GmbH
Enrollment: 8
Locations: 1
Primary Endpoint: Incidence of Alarms
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The aim of this clinical trial will be to verify the feasibility of using an impeller system instead of a roller pump for hemodialysis, using the established 4008 hemodialysis system and a Convergence Dialyzer with design changes made to the FX-Coral P 600 dialyzer.

Registry

clinicaltrials.gov

Start Date

January 19, 2022

End Date

February 22, 2022

Last Updated

4 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

D.med Consulting GmbH

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients must be up to 18-85 years
•Hemodialysis Schedule: 3 times per week; app. 3- 5 hour treatment
•Stable clinical conditions: no recent (last 2 weeks) hospitalization events, no recent main surgery (last 3 weeks), no acute cardiological problems, hemoglobine levels in the DOQI Guideline ranges.
•Hemodynamic stability during dialysis i.c. number of sessions complicated by acute hypotension events or arrhythmia \<25% in the last 3 Months
•Well-functioning AVF vascular access: access recirculation ≤10%
•No coagulation disorders and anticoagulant therapy
•Patients must be using a similar size dialyzer as Convergence dialyzer
•Signed Inform consent form.

Exclusion Criteria

•Unstable clinical condition: recent hospitalization, recent surgery, anemia, active neoplastic diseases,shock or unstable cardiac function and intolerable to extracorporeal treatment
•Hemodynamic instability during the dialysis sessions; more than 25% of the sessions complicated by acute hypotension or arrhythmic events.Presence of clinically significant abnormality on a 12-lead ECG at Screening that, at the investigator's clinical judgment, may compromise the safety of the patient or affect the outcome of the study.
•History or presence of congestive heart failure with symptoms consistent with New York Heart Association Class III or IV functional status within 6 months prior to the study Convergence system treatment.
•Abnormal liver function values including but not limited to the aspartate transaminase, alanine transaminase or alkaline phosphatase ≥5 × upper limit normal.
•Any uncontrolled clinically significant respiratory disease in the investigator's opinion (e.g., chronic obstructive pulmonary disease, cystic fibrosis, bronchiectasis, asthma).
•Temporary excluded will be patients with increased body temperature due to some infective disease, dehydration, diarrhea, hyperglycemia,
•Severe bleeding, or history or evidence of bleeding diathesis or coagulopathy with the risk of bleeding or have to put on dialysis without anticoagulant.
•Using temporary or permanent dialysis catheter
•Uncontrolled diabetes mellitus or hypertension, at the discretion of investigator.
•Known pregnancy and lactating without pregnancy test